Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who satisfy more than 4 criteria for diagnosis of systemic lupus erythematosus (ARA criteria, 1982)~* Patients who fall under WHO class III-IV lupus nephritis on renal biopsy~* Patients with refractory lupus nephritis~* Proteinuria ≥ 0.5 g/day~* Patients who took steroid ≥ 20 mg/day over one month prior to the study~* Patients who failed a first-line therapy (non-responders to steroid monotherapy)~Exclusion Criteria:~* Patients who are allergic or resistant to macrolide antibiotics or tacrolimus~* Patients who received tacrolimus in the past (excluding drugs for external use)~* Patients who used other immunosuppressants within 4 weeks before initiation of the study~* Patients who have been receiving systematic chemotherapy since before enrollment (local chemotherapy is allowed.)~* Patients with malignant tumor which developed within the recent 5 years or history of malignant tumor~* Patients who have severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorders which may influence absorption of tacrolimus~* Patients with S-Cr ≥ 200 µ㏖/L or ≥ 2.3 mg/dL~* Patients with liver function levels of more than twice the upper limit of normal or acute active hepatitis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus group (Type: EXPERIMENTAL): Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).